Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib for Brain Metastases in HER2-Positive Breast Cancer
NCT00098605Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in HER2-positive breast cancer, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate in the Central Nervous System up to 5 years. Started Oct 2004; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00098605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098605.